|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Revenue | |||||
| Product | |||||
| License | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross Profit, Total | |||||
| Costs and expenses: | |||||
| Cost of sales | |||||
| Cost of collaboration and license agreements revenue | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| Selling, general and administrative | |||||
| General and administrative | |||||
| Total costs and expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest income | |||||
| Interest expense | |||||
| Investment advisory fees | |||||
| Change in fair value of warrants liability | |||||
| Realized loss on marketable securities | |||||
| Realized gain (loss) on marketable securities | |||||
| Other expense | |||||
| Net loss on disposal of fixed assets | |||||
| Other income (expense) | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Other comprehensive loss, net of taxes: | |||||
| Currency translation adjustment | |||||
| Change in unrealized gain (loss) on available-for-sale securities | |||||
| Comprehensive loss | |||||
| Net loss per share attributable to common stockholders, basic | |||||
| Net loss per share attributable to common stockholders, diluted | |||||
| Weighted average common shares outstanding, basic | |||||
| Weighted average common shares outstanding, diluted | |||||
Loading...